AIforScience，重在AI+制药赛道

Industry Investment Rating - The investment rating for the computer industry is "Outperform the Market" and is maintained [1] Core Insights - The report highlights the significant growth potential in the AI and pharmaceutical sectors, with the global drug development outsourcing market expected to grow from USD 151.2 billion in 2023 to USD 363.2 billion by 2030, reflecting a CAGR of 13.3% [4][6] - Major North American companies are intensifying their efforts in AI and healthcare, with notable product launches and investments aimed at accelerating AI drug development [5] - The report emphasizes that AI has become a crucial "accelerator" in drug discovery, capable of efficiently learning complex relationships between molecular structures and biological activities, thus potentially transforming the pharmaceutical industry [7] Summary by Sections Industry Overview - The closing index for the computer industry is 5947.69, with a 52-week high of 6063.95 and a low of 4080.58 [1] Recent Developments - The report discusses the emergence of AI applications in the pharmaceutical sector, identifying key characteristics of successful AI applications, such as access to vast amounts of real data and the complexity of medical processes [4] - Companies like Crystal and TEMPUS are expected to achieve positive EBITDA for the first time in 2026, indicating a potential valuation restructuring in the industry [6] Investment Recommendations - The report suggests focusing on AI for Science and AI+pharmaceutical sectors, recommending companies such as Crystal Holdings, Insilico Medicine, and WuXi AppTec [10]